

ICPerMed, ERA PerMed, and the European Partnership for Personalised Medicine

Monika Frenzel, Agence National de la Recherche, ICPerMed / EU-Africa PerMed

EU-Africa PerMed 2nd Stakeholder Workshop, 21/02/2023



The future of medicine: Personalised Medicine (PM) – A definition

*PM [] “refers to a medical model using
 Characterisation of individuals’ phenotypes and genotypes
 (e.g. **molecular profiling, medical imaging, lifestyle data**)
 for tailoring the right **therapeutic** strategy for the right
 person at the right time,
 and/or to determine the **predisposition** to disease
 and/or to deliver timely and targeted **prevention**”.*

According to: Horizon 2020 and
 European Council Conclusions on personalised medicine for patients (2015/C 421/03)

Personalised Medicine: A major opportunity for society to provide benefits to patients and citizens and health systems


- Why does a treatment for a certain disease work very well for one patient, but poorly or not at all for another patient?
- Increasing genomic knowledge and data available:
How can the knowledge of an individual genetic profile or personal setting help to avoid health risks and support a healthy life?
- Vast amount of (digital) data available in future:
What is the benefit of individual molecular, clinical or lifestyle data for the development of personalised prevention, diagnostics, and treatment?
- Sustainable and efficient healthcare systems:
How can healthcare integrates the patient perspective, the right values, and socioeconomic aspects? Can the use of PM be cost effective?
- Medical devices:
How to provide access to healthcare (also in rural areas) and new technical developments, e.g. for diagnosis but also follow-up and prevention?

Personalised Medicine: A major opportunity for society to provide benefits to patients and citizens and health systems



Personalised Medicine is a principal driver towards optimised healthcare, due to its great potential for disease prevention, diagnostic and treatment.

How to prepare Europe but also collaborations on the global scale with the different heterogeneous regional and national healthcare systems for this improvement?

The (European) personalised medicine journey




The (international) personalised medicine journey




- Almost 50 European and international partners
- Members include public and private 'not-for-profit' health research funding and policy organisations and the European Commission

Overall aim: To coordinate and promote **research** along the full value chain to develop and evaluate personalised medicine approaches

The (international) personalised medicine journey



Alignment of strategies



Creation of evidence




https://www.icpermed.eu/en/best_practice_examples.php



Creation of synergies

- Events (conferences, workshops, training activities)
- Stakeholder Forum
- Partnering platform

The (international) personalised medicine journey



Joint Research Funding Programme

Dedicated to promote Personalised Medicine Research




ERA PerMed funders

- Steady partners (ERA PerMed beneficiaries): 32 partners from 23 countries (6 regions), EU and associated countries + Canada
- 10 more funders joined additional calls = in total 42 funders, incl. regional and international funders of 32 countries and 5 continents

International collaboration!

Besides Europe: Participation of North/South America, Asia and Africa!

The (international) personalised medicine journey



Joint Research Funding Programme

Dedicated to promote Personalised Medicine Research

Annual calls for proposals – 5 JTCs in total conducted


- More than 30 funders of around 20 countries per call
- Approx. 30 M€ total budget per call
- 111 projects funded with around 130 M€ total budget

Joint funding:

- Each funder is providing funding to applicants from his/her country
- Centralised call management – low personal costs for participation but high impact for the research community




The personalised medicine journey



The ICPeMed Family

CSA – coordination and support actions

- European Regions (2x)
- Clinical trials in PM
- Health economics
- Prevention in Personalised Medicine
- International collaboration: 4x (!!)
- 1x Latin and Caribbean countries
- 2x China
- **1x AFRICA**




International collaboration: Key to foster the uptake of personalised approaches in healthcare

- Excellent experts and initiatives located around the globe
- Reaching critical mass of data from various sources to develop and train algorithms and models used in PM approaches.
- ensuring that developed approaches are applicable as broadly as possible and not limited to a specific regional context → increase the value of developments for the common good.

Why this collaboration in the field of Personalised Medicine is so important


- Facilitating access to new tools and technologies.
- Contribute to shorten existing health disparities between developing and developed countries.
- Full implementation is complex and we need to join forces
- “Ensuring healthy lives for all at all ages” and make healthcare more efficient and equitable

Increasing commitment for and investment in PM



- Increased efforts in the PM field for PM research and implementation on regional and national level but also in collaborations across countries
- EC supporting joint efforts and activities related to PM to establishing Europe as a global leader in the field but also to foster cross boarder/international collaboration

The European Partnership for Personalised Medicine



None of the current and future challenges for Personalised Medicine can be solved by any one player alone.

All key players in the field need to work together across borders in order to solve the problems and progress in delivering Personalised Medicine to the citizen.

The European Partnership for Personalised Medicine

Draft proposal


A Common Vision:

*The vision of the European Partnership for Personalised Medicine is to **improve health outcomes** within **sustainable healthcare systems** through **research**, and the development and **implementation of personalised medicine approaches** for the benefit of patients, citizens and society.*


INFO-BOX EP PerMed

- **Running time:** 7 years
(10 years in total to allow annual EC co-funded calls)
- **Start end of 2023 - 2030**
- **Budget:** around 300 M€
- **EC-co-funding:** 30%
- **Governance:** beneficiaries and partners are regional/national funders and ministries only (currently proposed)
- **Open to international collaboration** (the “how” needs still to be decided)
- **Funding and strategic platform**
- **Based on a Strategic and Innovation Agenda**

The European Partnership for Personalised Medicine



Collaboration is the key to enable Personalised Medicine being the reality for citizens and patients



Collaboration is the key to enable Personalised Medicine being the reality for citizens and patients

Let us start to collaborate now

- **On all different levels:** Policy, regulation, legislation, healthcare systems, research-innovation-development
- **By including all relevant stakeholders:** citizens, patients, research, healthcare providers, industry, payers, funders, politicians
- **Cross sectors:** pre-clinic/clinic; data sciences; ethical, legal and social sciences, public and private sectors
- To **avoid duplications** and to **optimal use available resources** (e.g. infrastructures, data, samples, workforces, knowhow, etc.) more efficiently.
- To **invest more cost-effective in research, development and innovation.**

More information about ICPerMed

Mail: ICPerMed@dlr.de

Internet: www.icpermed.eu

Twitter: @ICPerMed

LinkedIn: @ICPerMed - The International Consortium for Personalised Medicine

More information about EP PerMed

eppermed@dlr.fr

Monika.frenzel@anr.fr